Gary Zammit, PhD, President and CEO of Clinilabs, speaks with Kelly Bilodeau from PharamVoice on how AI is reshaping clinical trials—particularly in mental health research.
When drugs fail, it’s not always because they’re ineffective, but because traditional trial designs rely heavily on subjective symptom ratings rather than objective biomarkers. In conditions such as depression and PTSD, this reliance can introduce bias, including inflated baseline scores that make it harder to detect true treatment effects. Zammit explains how AI-driven assessments are helping to reduce investigator bias, improve rating accuracy, and address long-standing challenges in CNS trials—ultimately increasing the likelihood of clinical success.
